Loading
A phase 2 trial of Glumetinib and Docetaxel in gastric & gastro-oesophageal junction cancer, run by CSPC ZhongQi Pharmaceutical Technology Co., Ltd., now recruiting.
Safety and Efficacy of Glumetinib Combined With Docetaxel for Injection (Albumin-bound) in Patients With Advanced Gastric Cancer/Gastroesophageal Junction Adenocarcinoma and Other Solid Tumors is a phase 2 interventional study registered as NCT06947291 by CSPC ZhongQi Pharmaceutical Technology Co., Ltd., with 350 participants planned, started 2025-06-04 and due to reach its primary completion in 2027-04-30. Interventions recorded: Glumetinib Tablets and Docetaxel for Injection (Albumin-bound).
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares CSPC Pharmaceutical Group, Docetaxel, Gastric & gastro-oesophageal junction cancer, Cytotoxic chemotherapy and the tag pipeline.
Shares CSPC Pharmaceutical Group, Docetaxel, Gastric & gastro-oesophageal junction cancer, Cytotoxic chemotherapy and the tag pipeline.
Shares Docetaxel, Gastric & gastro-oesophageal junction cancer, Cytotoxic chemotherapy and the tag pipeline.
Shares CSPC Pharmaceutical Group, Small-molecule kinase inhibitors and the tag pipeline.
Shares CSPC Pharmaceutical Group, Small-molecule kinase inhibitors and the tag pipeline.
Shares Docetaxel, Cytotoxic chemotherapy and the tag pipeline.
Shares Docetaxel, Cytotoxic chemotherapy and the tag pipeline.
Shares CSPC Pharmaceutical Group and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/